American Gastroenterological Association (AGA) hosted the "Preparing for the NASH Epidemic: A Call to Action" conference virtually on July 10th, 2020. The conference agenda is below, complete with videos and PDF slide decks.Gastroenterology Diabetes Care Metabolism Obesity .
Fasiha Kanwal, MD Baylor College of Medicine
Jay H. Shubrook, DO Touro University
Kenneth Cusi, MD University of Florida
Virtual Meeting Instructions
Session Chairs
Zobair M. Younossi, MD Inova Medicine Services
Yamini Natarajan, MD Baylor College of Medicine Current and Future Burden of NASH NASH Needs Assessment Survey Results
Session Chair
Elisabetta Bugianesi, MD, PHD University of Torino Pathogenesis of NAFLD/NASH Understanding the Risk of and Risk Factors Associated with Progression to Advanced Liver Disease in Patients with NAFLD Understanding the Risk of and Risk Factors Associated with Progression to Cardiovascular and Other Complications in Patients with NAFLD Who should be screened for NAFLD/NASH in primary care population? When is it necessary? Q&A on NASH led by Session Chair
Session Chairs
Stephen A. Harrison, MD Pinnacle Clinical Research
Christos Mantzoros, MD Harvard Medical School (Endocrine Society) Initial Evaluation of Patients with NAFLD: Clinical and Laboratory Testing in Primary Care Initial Evaluation of Patients with NAFLD: Imaging, Other Non-invasive Testing in Primary Care Who and When Should I Refer my Patient to a Hepatologist? To an Endocrinologist? Role of Biopsy in NAFLD/NASH Bringing It All Together: Key Components in the Initial Evaluation and Referral of Patients with NAFLD; Role of Liver Biopsy, Non-Invasive Testing, and Risk Prediction Algorithms Q&A on Diagnosing NASH led by Session Chairs
Session Chairs
Robert H. Eckel, MD University of Colorado (ADA)
Sam Klein, MD Washington University Lifestyle Interventions for NAFLD and NASH: What Works and What Does Not Work for Patients with NAFLD Pharmacotherapy: Expanding Care Beyond Diet and Exercise in NASH Management: Who should get it? Surgical and Endoscopic Treatment Options in Patients with NAFLD/NASH Co-management of T2DM and NASH: Current and Future Perspectives Q&A on NASH Management led by Session Chairs
Session Chair
Hashem El-Serag, MD Baylor College of Medicine (AGA) Primary Care Provider Panel: Patient-Centered Medical Home for NAFLD/NASH Moderator: Jay H. Shubrook, DO, Touro University Panelist: William Herman, MD, University of Michigan Panelist: Neil Skolnik, MD, Temple University Panelist: Davida Kruger, MSN, Henry Ford Health System Panelist: Eugene Wright, MD, Duke University Ongoing Surveillance of Patients with NAFLD/NASH: Who Can Be Managed in Primary Care; Frequency of Follow Up; Type of Surveillance Testing (Repeating Non-invasive Testing); Secondary Prevention Screening for Liver Cancer in Patients with NAFLD What Tools Do We Need to Improve Diagnosis and Management of NAFLD/NASH Future Directions: What Are We Expecting? Screening, Risk Stratification, and Treatment. Q&A on What Tools Do We Have and What Do We Need?
Watch recording of the full EoE Disease Severity Index Conference here. VIDEO
